ICU Medical, Inc. — FY2020 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2020. ICU Medical is a global medical-device company focused on infusion therapy, with products spanning infusion consumables, infusion systems, IV solutions and critical care. The company reports one operating segment and sells in more than 90 countries.
Financial performance and liquidity
Amounts are in U.S. dollars; annual figures are for fiscal years ended December 31.
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $1,271.0 million | $1,266.2 million |
| Gross profit / gross margin | $461.5 million / 36.3% | $471.9 million / 37.3% |
| Operating income | $98.2 million | $107.4 million |
| Net income | $86.9 million | $101.0 million |
| Diluted EPS | $4.02 | $4.69 |
| Cash from operating activities | $222.8 million | $101.9 million |
| Capital expenditures | $92.0 million | $97.3 million |
At year-end, cash, cash equivalents and investment securities totaled $410.8 million; working capital was $725.3 million. ICU had no borrowings outstanding on its $150 million revolving credit facility, which was fully available, and reported compliance with its financial covenants. Total assets were $1.764 billion and stockholders’ equity was $1.502 billion.
Fourth quarter: Revenue was $320.5 million versus $315.5 million in Q4 2019; net income was $26.1 million versus $20.6 million; diluted EPS was $1.21 versus $0.96.
Material changes versus the prior comparable period
- Full-year revenue edged up 0.4%, but net income fell 14.0% and gross margin declined 1.0 percentage point.
- Infusion Systems revenue rose 9.6% to $359.7 million, driven mainly by pandemic-related demand for pumps. Infusion Consumables revenue slipped 0.8% to $473.7 million, reflecting lower demand for certain sets. IV Solutions revenue fell 6.3% to $389.0 million, including lower Pfizer contract-manufacturing sales. Critical Care revenue increased 7.3% to $48.6 million.
- Management attributed lower gross margin primarily to reduced IV Solutions manufacturing volumes and unfavorable product mix as demand for consumables weakened. SG&A rose 2.5%; R&D declined 11.7% to $42.9 million.
- Operating cash flow more than doubled, partly reflecting collections and lower receivables and inventory. Investing cash outflow decreased to $98.1 million from $166.9 million, including the prior-year Pursuit acquisition.
- Restructuring, strategic transaction and integration costs declined to $28.4 million from $80.6 million. The 2020 results also included a $9.0 million increase in the fair value of the Pursuit earn-out liability.
Outlook, commentary and risks
- No specific revenue or earnings guidance is provided. Management estimated 2021 capital expenditures of approximately $75–$85 million and said existing cash and expected operating cash flows should fund operations for the next 12 months.
- COVID-19 reduced demand for non-dedicated consumables and dedicated infusion sets, while increasing demand for infusion-pump hardware. Management said the pandemic’s future effects remain uncertain and cannot yet be quantified; risks include further demand shifts, supply interruptions, implementation delays, added costs and customer payment pressure.
- Key risks include reliance on sole- or limited-source suppliers and concentrated manufacturing at certain facilities; intense competition and pricing pressure; regulatory, product-quality and product-liability exposure; cybersecurity and privacy risks; foreign-exchange volatility; and integration and execution risks.
- Pfizer disputes ICU’s determination that no performance-based earn-out was payable for the 2017 Hospira Infusion Systems acquisition. The dispute was expected to proceed to binding arbitration absent an agreement. Separately, the Pursuit acquisition earn-out could reach $50 million; its recorded fair value was $26.3 million at year-end.
- The company reported no material adverse impact expected from routine unsettled legal proceedings. Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting. The audit identified the chargeback reserve as a critical audit matter because of estimation judgment.
Important facts for investors to verify
- Progress and resolution of the Pfizer earn-out dispute, including any potential cash exposure.
- Actual 2021 capital spending and whether the expected demand and product mix support recovery in gross margin.
- Changes in pandemic-related demand, customer ordering and implementation of infusion systems.
- Chargeback-reserve estimates and collections, given the auditor’s identification of this estimate as a critical audit matter.
- Supplier and facility continuity, the Pursuit earn-out liability, and continued compliance with credit-facility covenants.